发明名称 METHODS AND NUCLEOTIDE FRAGMENTS OF PREDICTING OCCURRENCE, METASTASIS OF CANCERS AND PATIENTS' POSTOPERATIVE SURVIVAL IN VITRO
摘要 Provided in the present invention are a method using in vitro measurement of the content of methylation or demethylation of GFRal CpG islands to estimate a risk of tumorigenesis and of tumor metastasis, or postoperative life expectancy, and a nucleotide sequence used.
申请公布号 US2016040243(A1) 申请公布日期 2016.02.11
申请号 US201214378285 申请日期 2012.02.13
申请人 Deng Dajun;Zhang Jun;Liu Zhaojun;Zhou Jing;Gu Liankun;Zhang Baozhen 发明人 Deng Dajun;Zhang Jun;Liu Zhaojun;Zhou Jing;Gu Liankun;Zhang Baozhen
分类号 C12Q1/68 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method of detection of occurrence of cancers in vitro, characterized in that said method comprises the following steps: a) Extracting tissue DNA or plasma free DNA from certain number of cancer and non-cancer patients respectively; b) Detecting and calculating proportion of methylated or demethylated GFRa1 CpG islands; setting a cutoff value for detection of cancers using the proportion of methylated or demethylated GFRa1; c) Extracting tissue DNA or plasma free DNA samples from testing subjects in vitro, detecting and calculating proportion of methylated or demethylated GFRa1 CpG islands in the DNA samples; d) Comparing the proportion of methylated or demethylated GFRa1 determined in the step c) with the cutoff value set in the step b); e) If the proportion of methylated GFRa1 determined in the step c) is less than or equal to said cutoff value set in the step b), it is considered the occurrence of cancer, otherwise, occurrence of cancer is not considered; or, if the proportion of demethylated GFRa1 determined in the step c) is higher than or equal to said cutoff value set in the step b), it is considered the occurrence of cancer, on the contrary, cancer occurrence is not considered.
地址 Beijing CN